ADA Scientific Sessions 2025 Abstract
Targeting Activin Type II Receptors—Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction
Experiments in animalsInterventions
Papers by Lin Xiaofen
1 result